Antibody-drug conjugates (ADC) have emerged. There are several key points in the design of antibody-conjugated drugs: 1) suitable targets can specifically target tumor cells; 2) antibodies corresponding to them can accurately find targets; 3) cytotoxins, which have sufficient toxic effects to kill Tumor cells; 4) ADC linkers that link antibodies to cytotoxins to ensure that they do not break in the circulatory system of the body, but break within the tumor cells and release cytotoxins; 5) Link antibodies, cytotoxins and linkers together The combination of technology. The production of these three substances involves both biotechnology and chemical synthesis. Toxic payload drugs are an essential component of any therapeutic ADC. In reality, not every toxin is suitable to be used as an adc payload.
https://www.creative-biolabs.com/adc/drug-module.htm